Pediatric COVID-19 cases have seen a recent exponential increase, the group notes, con quasi 500,000 cases added from Aug. 26 to Sept. 9, the most recent available figures. The latest report also reflects an almost 240% increase in weekly cases since late July, quando 71,726 cases were reported.
The pediatric group’s prior report, including data through Sept. 2, saw the number of weekly pediatric COVID-19 cases climb to the highest figure seen since the pandemic began, a 251,781 infezioni. The group continues to urge further research into the pandemic’s long-term impacts on kids, including physical, emotional and mental health effects.
Complessivamente, al di sopra di 5.2 million COVID-19 cases have been reported among children since the pandemic began, however infections resulting in severe illnesses is uncommon, the latest report reads.
The findings coincide with a continued surge in the rate of new hospital admissions for patients aged 0-17, which as of Sept. 5, reached 0.50 admissions per 100,000 population, secondo dati dai Centers for Disease Control and Prevention (Centro per la prevenzione e il controllo delle malattie). In early July, the rate was approximately 0.07 per 100,000. Adults over age 70 hold the highest rate of new admissions at about 8 per 100,000. By late August, weekly cases per 100,000 were highest among teens aged 16-17, a 326.9, compared to all other age groups.
Children under age 12 remain ineligible for COVID-19 vaccine, though shots could become available later in the fall. Dott. Scott Gottlieb, former FDA commissioner and Pfizer board member, detto CNBC that Pfizer will likely request emergency approval for use of its vaccine among kids aged 5 per 11 in ottobre, with potential authorization by late fall or early winter. Nel frattempo, Moderna’s trial data for kids ages 5-11 could come by late fall or early winter, Insider segnalato.
“The FDA is working around the clock to support the process for making COVID-19 vaccines available for children,” the Food and Drug Administration wrote in a Sept. 10 dichiarazione, adding in part, “this process is complex and relies on robust manufacturer trials and data.”